Paper 59 - COMBINATION OF ONCOLYTIC VIROTHERAPY WITH ISOLATED LIMB PERFUSION IN ADVANCED UNRESECTABLE EXTREMITY SARCOMA RESULTS IN IMMUNE ACTIVATION: RESULTS OF A PHASE I/II CLINICAL TRIAL

Author(s)

• 

  Andrew J. Hayes, MD PhD

  Consultant Surgical Oncologist
  Royal Marsden Hospital
  London, England, United Kingdom

  Slides PDF

Co-Author(s)

• ED

  Emma Davies, MD

  Institute of Cancer Research
  London, England, United Kingdom
• HS

  Henry Smith, MD PhD

  Institute of Cancer Research
  London, England, United Kingdom
• PN

  Pablo Nenclares, MD (he/him/his)

  Clinical Research Fellow
  Institute of Cancer Research
  London, England, United Kingdom
• DM

  David Mansfield, PhD

  Institute of Cancer Research
  London, England, United Kingdom
• VR

  Victoria Roulstone, PhD

  Institute of Cancer Research
  London, England, United Kingdom
• JK

  Joan Kyula-Currie, PhD

  Institute of Cancer Research
  London, England, United Kingdom
• AR

  Antonio Rullan, MD

  Institute of Cancer Research
  London, England, United Kingdom
• EP

  Emmanuel Patin, PhD

  Institute of Cancer Research
  London, England, United Kingdom
• MP

  Malin Pedersen, PhD

  Institute of Cancer Research
  London, England, United Kingdom
• KM

  Kabir Mohammed, n/a

  The Royal Marsden NHS Foundation Trust
  London, England, United Kingdom
• 

  Myles JF Smith, MB BCh BAO, PhD, FRCSI, FRCS

  Surgical Oncologist
  Sarcoma Unit, Royal Marsden Hospital
  London, England, United Kingdom
• AF

  Andrew Furness, MD PhD

  Royal Marsden Hopsital
  London, England, United Kingdom
• RJ

  Robin L. Jones, MD, PhD

  The Royal Marsden NHS Foundation Trust
  London, England, United Kingdom
• 

  Alan Melcher, MD PhD

  Professor of Translational Immunotherapy
  Institute of Cancer Research
  London, England, United Kingdom
• KH

  Kevin Harrington, MD PhD

  Institute of Cancer Research
  London, England, United Kingdom